Repaglinide

REPAGLINIDE

Manufacturer: Sun Pharmaceutical Industries, Inc.

Score: 141.0

Quick Summary

Repaglinide is an oral blood glucose-lowering drug used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It works by stimulating the release of insulin from the pancreas and is available in 1 mg and 2 mg tablet forms. The recommended starting dose is 0.5 mg to 1 or 2 mg orally before each meal, with a maximum daily dose of 16 mg. Repaglinide is contraindicated in patients with concomitant use of gemfibrozil, known hypersensitivity to repaglinide, or severe renal impairment. Common adverse reactions include hypoglycemia, upper respiratory infection, headache, and sinusitis. Special population considerations include use during pregnancy, pediatric use, and geriatric use.

Key Clinical Findings and Indications

Repaglinide is used to improve glycemic control in adults with type 2 diabetes mellitus.
It is an adjunct to diet and exercise.
Repaglinide stimulates the release of insulin from the pancreas.

Important Safety Information

Warning

Hypoglycemia is a common adverse reaction, and patients should be instructed on how to manage it.

Contraindications

Concomitant use of gemfibrozil
Known hypersensitivity to repaglinide
Severe renal impairment

Adverse Reactions

Hypoglycemia
Upper respiratory infection
Headache
Sinusitis

Dosing Recommendations

General Guidance

The dose should be adjusted based on the patient's response to therapy, and the maximum daily dose should not exceed 16 mg.

Type 2 diabetes mellitus

Adult Dose

0.5 mg to 1 or 2 mg orally before each meal

Pediatric Dose

Not established

Special Population Considerations

Pregnancy

Limited data available on the use of repaglinide during pregnancy
Repaglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Nursing Mothers

It is not known whether repaglinide is excreted in human milk
Caution should be exercised when repaglinide is administered to a nursing woman

Pediatric Use

Safety and effectiveness have not been established in pediatric patients

Geriatric Use

No differences in effectiveness or adverse events were seen in patients over 65 years of age compared to those less than 65
Greater sensitivity of some older individuals to repaglinide cannot be ruled out

Similar Drugs

Pioglitazole and metformin hydrochloride

PIOGLITAZOLE AND METFORMIN HYDROCHLORIDE

Macleods Pharmaceuticals Limited

Similarity: 62.3%

Pioglitazone Hydrochloride and Metformin Hydrochloride

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AvKARE

Similarity: 61.2%

Pioglitazone

PIOGLITAZONE

Aphena Pharma Solutions - Tennessee, LLC

Similarity: 60.6%

ZITUVIO

SITAGLIPTIN

Zydus Pharmaceuticals (USA) Inc.

Similarity: 60.3%